University of Franche-Comté Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Besancon France (1423)

Organization Overview

First Clinical Trial
1998
NCT01559753
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Besancon University | Besancon University Hospital | Célia Turco | Centre Hospitalier Universitaire de Besançon | Centre Hospitalier Universitaire de Besancon | CH BESANCON | CHRU Besancon | CHU Besancon, France | CHU de Besancon | CHU Jean Minjoz-BESANCON | Nephrology, Dialysis and Renal Transplantation - CHU Besançon | University Hospital of Besancon

Active Ingredients

Drugs in Phase 4 Trials (11)

cefotaxime (claforan) (2 trials)

ceftriaxone (rocephin) (2 trials)

clavulanate (Augmentin) (1 trial)

dalfampridine (ampyra) (1 trial)

glycopyrronium (robinul) (1 trial)

indacaterol (arcapta neohaler) (1 trial)

netilmicin (netromycin) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

tiotropium (spiriva) (1 trial)

tobramycin (nebcin) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 3 Trials (34)

acetaminophen (tylenol) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

albumin (Human) (Plasbumin) (1 trial)

anastrozole (arimidex) (1 trial)

atorvastatin (lipitor) (1 trial)

bortezomib (velcade) (1 trial)

capsaicin (qutenza) (1 trial)

cefepime (maxipeme) (1 trial)

dexamethasone (2 trials)

elbasvir (1 trial)

exenatide (byetta) (2 trials)

grazoprevir (zepatier) (1 trial)

indocyanine green (ic-green) (1 trial)

insulin human (humulin) (2 trials)

lactic acid (1 trial)

letrozole (femara) (1 trial)

mannitol (Osmitrol) (1 trial)

melphalan (alkeran) (1 trial)

meropenem (merrem) (1 trial)

morphine (1 trial)

mycophenolate (CellCept) (1 trial)

oxygen (3 trials)

piperacillin (pipracil) (1 trial)

ramipril (altace) (1 trial)

remifentanil (ultiva) (1 trial)

rifaximin (xifaxan) (1 trial)

rimabotulinumtoxinB (Myobloc) (2 trials)

rituximab (rituxan) (1 trial)

ropivacaine (naropin) (2 trials)

sodium chloride (2 trials)

tazobactam (Zosyn) (1 trial)

urea (1 trial)

vildagliptin (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (40)

asparaginase (elspar) (1 trial)

atezolizumab (Tecentriq) (2 trials)

autologous apoptotic cells (1 trial)

avelumab (bavencio) (1 trial)

bevacizumab (avastin) (5 trials)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

capecitabine (xeloda) (3 trials)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (4 trials)

cyclophosphamide (cytoxan) (3 trials)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (1 trial)

estramustine (emcyt) (1 trial)

fluorouracil (efudex) (4 trials)

fosfomycin (monurol) (1 trial)

gemcitabine (gemzar) (1 trial)

idarubicin (idamycin) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

inulin (1 trial)

irinotecan (Camptosar) (3 trials)

lactobacillus bulgaricus (1 trial)

lactobacillus casei (1 trial)

lactobacillus plantarum (1 trial)

leucovorin (3 trials)

methotrexate (1 trial)

naltrexone (revia) (1 trial)

omalizumab (xolair) (1 trial)

oxaliplatin (eloxatin) (5 trials)

oxytocin (syntocinon) (2 trials)

paclitaxel (taxol) (1 trial)

Raltitrexed (1 trial)

regorafenib (stivarga) (1 trial)

Streptococcus thermophilus (1 trial)

sunitinib (sutent) (1 trial)

tacrolimus (prograf) (1 trial)

t lymphocytes (1 trial)

ucpvax (4 trials)

Drugs in Phase 1 Trials (5)

aldesleukin (Proleukin) (1 trial)

allogeneic adipose derived mesenchymal stem cell (1 trial)

allogeneic natural killer cells (1 trial)

clofarabine (clolar) (1 trial)

fludarabine (fludara) (1 trial)

Drugs in Other Trials (5)

apolipoprotein (1 trial)

benzimidazole (1 trial)

levobupivacaine (chirocaine) (1 trial)

n2-l-alanyl-l-glutamine (1 trial)

x34 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Adenocarcinoma (Phase 2)

Aneurysm (Phase 3)

Anus Neoplasms (Phase 2)

Aortic Aneurysm (Phase 3)

Aortic Aneurysm, Abdominal (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Ascites (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiovascular Diseases (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 4)

Diabetes Mellitus (Phase 3)

Disease Progression (Phase 2)

Ear Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 2)

Fibrosis (Phase 3)

Forearm Injuries (Phase 3)

Glioblastoma (Phase 2)

Graft vs Host Disease (Phase 2)

Hemiplegia (Phase 3)

Hepatitis C (Phase 3)

Hyperglycemia (Phase 3)

Infarction (Phase 3)

Infections (Phase 4)

Intracranial Hypertension (Phase 3)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Diseases (Phase 4)

Lung Diseases, Interstitial (Phase 3)

Lung Diseases, Obstructive (Phase 4)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 4)

Muscle Spasticity (Phase 3)

Myocardial Infarction (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Neuroendocrine Tumors (Phase 2)

Penile Neoplasms (Phase 2)

Peritonitis (Phase 3)

Pneumonia (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Recurrence (Phase 1)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Sclerosis (Phase 4)

Shock (Phase 3)

Shock, Septic (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Stroke (Phase 1)

Syndrome (Phase 3)

Ulcer (Phase 2)

Urinary Tract Infections (Phase 2)

Urticaria (Phase 2)

Vulvar Vestibulitis (Phase 3)

Vulvodynia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 95